We are actively engaged in the development of novel drug delivery systems (NDDS) such as Liposomes, Nanoparticles, and Micro-particulate systems. Notably, we are pioneers in the successful development and commercialization of Nanoparticle-Albumin-Bound Paclitaxel, Ready-to-Use Docetaxel, and Gemcitabine, distinguishing us as leaders in the field.
Moreover, our research efforts extend to New Drug Delivery Systems (NDDS), PARP Inhibitors, and Targeted Therapies (NIBs), reflecting our commitment to innovation and advancement in cancer treatment.
With one of the most robust product pipelines in targeted therapies, encompassing various stages of development, we remain at the forefront of revolutionizing cancer therapeutics.
Patient-Centric Research: Meeting Healthcare Needs Through Innovation
Beta Drugs Limited stands among the select few Indian oncology pharmaceutical companies that recognize the paramount importance of research and development, investing significantly in these endeavors. Our team comprises highly accomplished scientists dedicated to both process and analytical work.
